Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 228Neoplasm Metastasis 17Breast Neoplasms, Male 7Breast Diseases 7Neoplasms 6Carcinoma, Intraductal, Noninfiltrating 4Recurrence 3Obesity 3Breast Carcinoma In Situ 3Breast Cancer Metastatic 3Advanced Breast Cancer 3Neoplasms by Site 2Bulbo-Spinal Atrophy, X-Linked 2Arthralgia 2Vitamin D Deficiency 1Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sleep Wake Disorders 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Primary Breast Cancer ER+ve 1Premenopausal Breast Cancer 1Post Menopausal Women With Early Breast Cancer 1Patient Acceptance of Health Care 1Pain 1

Interventions

exemestane 1Paclitaxel 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
First Line Metastatic Breast Cancer × exemestane × Breast × Clear all
NCT01303679 2023-09-06

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

ARCAGY/ GINECO GROUP

Phase 3 Terminated
117 enrolled
Breast

First Line Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡